Delayed breast cancer relapse with pleural metastasis and malignant pleural effusion after long periods of disease-free survival

被引:8
|
作者
Rawindraraj, Antony Divananth [1 ]
Zhou, Christine Yang [1 ]
Pathak, Vikas [1 ,2 ]
机构
[1] Campbell Univ, Sch Osteopath Med, Dept Internal Med, Lillington, NC USA
[2] WakeMed Hlth & Hosp, Dept Pulm & Crit Care Med, Raleigh, NC USA
来源
RESPIROLOGY CASE REPORTS | 2018年 / 6卷 / 09期
关键词
Breast cancer relapse; breast cancer metastasis; malignant pleural effusion; pleural effusion;
D O I
10.1002/rcr2.375
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Breast cancer relapse remains a common cause of morbidity and mortality in patients who undergo initial treatment with surgery and with or without concurrent chemotherapy or radiation. Relapse rates remain high within the first decade after initial treatment, after which the risk of relapse decreases. While common within the first year of breast cancer diagnosis, pleural metastasis with malignant pleural effusion (MPE) after 10-12 years of a disease-free period is rare. Here, we present two uncommon cases of delayed breast cancer relapses with pleural metastasis, which caused MPEs.
引用
收藏
页数:3
相关论文
共 40 条
  • [31] MALIGNANT PLEURAL MESOTHELIOMA AFTER RADIATION-THERAPY FOR BREAST-CANCER - A REPORT OF 2 ADDITIONAL PATIENTS
    SHANNON, VR
    NESBITT, JC
    LIBSHITZ, HI
    CANCER, 1995, 76 (03) : 437 - 441
  • [32] Muscle mass cross-sectional area is associated with survival outcomes in malignant pleural disease related to lung cancer
    Meggyesy, Austin M.
    Wilshire, Candice L.
    Chang, Shu-Ching
    Gorden, Jed A.
    Gilbert, Christopher R.
    RESPIRATORY MEDICINE, 2023, 217
  • [33] Establishment and characterization of 24 breast cancer cell lines and 3 breast cancer organoids reveals molecular heterogeneity and drug response variability in malignant pleural effusion-derived models
    Kim, Soon-Chan
    Kim, Ga-Hye
    Park, Jae-Hyeon
    Lee, Kyung-Hun
    Koh, Jiwon
    Kim, Tae-Yong
    Lee, Dae-Won
    Kim, Yu-Jin
    Kim, Seongyeong
    Park, Song-Yi
    Min, Ahrum
    Shin, Young-Kyoung
    Im, Seock-Ah
    Ku, Ja-Lok
    BREAST CANCER RESEARCH, 2025, 27 (01)
  • [34] Distinct profile of cell-free DNA in malignant pleural effusion of non-small cell lung cancer and its impact on clinical genetic testing
    Yu, Yongfeng
    Qian, Jie
    Shen, Lan
    Ji, Wenxiang
    Lu, Shun
    INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, 2021, 18 (06): : 1510 - 1518
  • [35] THERAPEUTIC AND LIFE-PROLONGING EFFECT OF INTRAPLEURAL INJECTION WITH A STREPTOCOCCAL PREPARATION, OK-432, AND IL2-CULTURED EFFUSION LYMPHOCYTES TO BREAST-CANCER PATIENTS WITH MALIGNANT PLEURAL EFFUSION
    HORI, T
    MISE, K
    KAN, N
    OKINO, T
    SATOH, K
    YAMASAKI, S
    TERAMURA, Y
    HARADA, T
    OHGAKI, K
    KODAMA, H
    TOBE, T
    BIOTHERAPY, 1992, 5 (01) : 21 - 29
  • [36] Nomogram construction for predicting survival of patients with non-small cell lung cancer with malignant pleural or pericardial effusion based on SEER analysis of 10,268 patients
    Tian, Tian
    Zhang, Pengpeng
    Zhong, Fei
    Sun, Cuiling
    Zhou, Jian
    Hu, Wenjun
    ONCOLOGY LETTERS, 2020, 19 (01) : 449 - 459
  • [37] Malignant pleural disease is highly associated with subsequent peritoneal metastasis in patients with stage IV non-small cell lung cancer independent of oncogene status
    Patil, Tejas
    Aisner, Dara L.
    Noonan, Sinead A.
    Bunn, Paul A.
    Purcell, William T.
    Carr, Laurie L.
    Camidge, D. Ross
    Doebele, Robert C.
    LUNG CANCER, 2016, 96 : 27 - 32
  • [38] Next-generation sequencing reveals mutational accordance between cell-free DNA from plasma, malignant pleural effusion and ascites and directs targeted therapy in a gastric cancer patient
    Zhou, Shujuan
    Xu, Bo
    Qi, Liang
    Zhu, Dongqin
    Liu, Baorui
    Wei, Jia
    CANCER BIOLOGY & THERAPY, 2019, 20 (01) : 15 - 20
  • [39] Clinical factors affecting the survival of patients diagnosed with non-small cell lung cancer and metastatic malignant pleural effusion, treated with hyperthermic intrathoracic chemotherapy or chemical talc pleurodesis: a monocentric, prospective, randomized trial
    Kleontas, Athanasios
    Sioga, Antonia
    Pandria, Niki
    Barbetakis, Nikolaos
    Lazopoulos, Achilleas
    Katsikas, Ioannis
    Asteriou, Christos
    Paliouras, Dimitrios
    Kamperis, Efstathios
    Ikonomou, Dimitrios
    Papamitsou, Theodora
    Filippou, Dimitrios
    Destouni, Chariklia
    Ikonomou, Louiza
    Zarogoulidis, Konstantinos
    Papagiannopoulos, Kostas
    JOURNAL OF THORACIC DISEASE, 2019, 11 (05) : 1788 - 1798
  • [40] Treatment outcome comparisons between exons 19 and 21 EGFR mutations for non-small-cell lung cancer patients with malignant pleural effusion after first-line and second-line tyrosine kinase inhibitors
    Zheng, Zhen
    Xie, Deyao
    Su, Huafang
    Lin, Baochai
    Zhao, Lihao
    Deng, Xia
    Chen, Hanbin
    Fei, Shaoran
    Jin, Xiance
    Xie, Congying
    TUMOR BIOLOGY, 2017, 39 (06)